Cellular Biomedicine Group certified to ISO 9001:2008 and ISO-14644

Published: 19-Feb-2013
Regulatory Pharmaceutical

Only cell therapy company in China to be awarded ISO 9001:2008 by SGS


Cellular Biomedicine Group (CBMG), a developer of cell therapies for the treatment of certain degenerative diseases, has achieved both ISO 9001:2008 certification and ISO-14644 cleanroom certification.

Shanghai, China-based Cellular Biomedicine Group has been accredited the ISO 9001:2008 certification by inspection, verification, testing and certification company SGS. The American National Accreditation Bureau (ANAB) issued the certificate. ISO 9001:2008 addresses the requirements for implementing an efficient quality management system.

In addition, since 2012 CBMG has maintained an ISO-14644 cleanroom certification from ENV Services. ENV is an ISO-accredited, US-based testing and certification company, certified in Cleanroom Performance Testing according to the NEBB (National Environmental Balancing Bureau).

“We are extremely proud to obtain ISO 9001:2008 and ENV certification, which are important milestones in the development of our company,” said CBMG President Dr William Cao. “It is a significant achievement that demonstrates the commitment to a level of excellence upon which our partners can depend. We look forward to announcing additional milestones as we continue to execute on our growth strategy.”

  • Companies:
  • Cellular Biomedicine Group CBMG
See more

You may also like

Manufacturing

CBMG accelerates cell therapy manufacturing

Read more
GE Healthcare’s new start-to-finish solution — FlexFactory — for cell therapy installation will provide Cellular Biomedicine Group (CBMG) with scalable, fully-equipped cell therapy manufacturing capabilities, training and services

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  3. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. Sanofi Pasteur launches 5-in-1 combination vaccine in China New vaccine Pentaxim reduces number of infant injections from 12 to four
  5. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

CBMG accelerates cell therapy manufacturing

GE Healthcare’s new start-to-finish solution — FlexFactory — for cell therapy installation will provide Cellular Biomedicine Group (CBMG) with scalable, fully-equipped cell therapy manufacturing capabilities, training and services
Research & Development

CBMG and GE Healthcare China establish joint tech lab

Research and development collaboration to take place in Cellular Biomedicine GMP facilities
Distribution

Tower Cold Chain’ industry-first shipping container design

The pyramidal solution allows pharmaceuticals to be shipped at a consistent temperature between -60°C to above +20°C for up to 96 hours
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Pharmaceutical

High-precision temperature control solutions for the pharmaceutical industry and biotechnology, available in the UK from Labtex

Huber offers a world-renowned range of temperature control systems and associated accessories for the Pharmaceutical Industry and Biotechnology
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Subscribe now